ANI Pharmaceuticals, Inc. (ANIP)
Automate Your Wheel Strategy on ANIP
With Tiblio's Option Bot, you can configure your own wheel strategy including ANIP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANIP
- Rev/Share 37.6827
- Book/Share 22.0206
- PB 4.1597
- Debt/Equity 0.7329
- CurrentRatio 2.5445
- ROIC 0.0094
- MktCap 1986694080.0
- FreeCF/Share 5.615
- PFCF 17.839
- PE -164.699
- Debt/Assets 0.2383
- DivYield 0
- ROE -0.0254
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ANIP | H.C. Wainwright | -- | Buy | -- | $84 | July 10, 2025 |
| Initiation | ANIP | Jefferies | -- | Buy | -- | $80 | March 14, 2025 |
| Initiation | ANIP | JP Morgan | -- | Overweight | -- | $85 | March 12, 2025 |
| Initiation | ANIP | Leerink Partners | -- | Outperform | -- | $80 | Dec. 11, 2024 |
| Initiation | ANIP | Piper Sandler | -- | Overweight | -- | $68 | Oct. 11, 2024 |
News
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross?
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals, Inc. (ANIP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ANIP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Read More
Wall Street Analysts Think ANI (ANIP) Could Surge 26.83%: Read This Before Placing a Bet
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for ANI (ANIP) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Relative Price Strength: A Smart Strategy Amid Market Turmoil
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
OOMA, ANIP, MATX, VIRT and EVER are five stocks with explosive relative price strength.
Read More
Wall Street Analysts Believe ANI (ANIP) Could Rally 32.4%: Here's is How to Trade
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for ANI (ANIP) points to a 32.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Read More
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
Read More
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in a prefilled syringe format. This new presentation will be available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options through Cortrophin Gel's established specialty pharmacy network. The prefilled syringe reduces administration steps for patients using Cortrophin Gel, which remains available in 5 mL and 1 mL vials. For full indications and important safety information, please see below.
Read More
ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q4 2024 Earnings Conference Call February 28, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants David Amsellem - Piper Sandler Vamil Divan - Guggenheim Securities Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Oren Livnat - H.C. Wainwright Jeevan Larson - Truist Securities Glen Santangelo - Jefferies Operator Good morning, everyone.
Read More
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
BAUDETTE, Minn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and full year ended December 31, 2024.
Read More
ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows: Raymond James & Associates' 46 th Annual Institutional Investors Conference Tuesday, March 4, 2025, at 1:40pm ET Leerink Partners Global Healthcare Conference Tuesday, March 11, 2025, at 3:40pm ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceuticals.com , under the Investors section under Events and Presentations.
Read More
About ANI Pharmaceuticals, Inc. (ANIP)
- IPO Date 2000-05-05
- Website https://www.anipharmaceuticals.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Nikhil Lalwani
- Employees 897